First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers

BACKGROUND: Inhibition of the epithelial sodium channel (ENaC) represents a mutation-agnostic therapeutic approach to restore airway surface liquid hydration and mucociliary clearance in patients with cystic fibrosis. BI 1265162 is an inhaled ENaC inhibitor with demonstrated preclinical efficacy. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Mackie, Alison, Rascher, Juliane, Schmid, Marion, Endriss, Verena, Brand, Tobias, Seibold, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7861022/
https://www.ncbi.nlm.nih.gov/pubmed/33569494
http://dx.doi.org/10.1183/23120541.00447-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7861022/
https://www.ncbi.nlm.nih.gov/pubmed/33569494
http://dx.doi.org/10.1183/23120541.00447-2020

Ejemplares similares